This segment focuses on the development, manufacturing, and commercialization of diagnostic kits and instruments for detecting various infectious diseases. Research and development activities include the creation of real-time PCR assays and nucleic acid extraction kits for pathogens like SARS-CoV-2, influenza, and other respiratory viruses. Technologies employed encompass advanced magnetic bead technology and one-tube fast release technology to improve accuracy and speed. The segment addresses the need for rapid and reliable diagnosis of infectious diseases, impacting patient outcomes through timely treatment and disease control. Sansure Biotech holds a strong market position in China and is expanding internationally. Future opportunities lie in expanding the product portfolio to include tests for emerging infectious diseases and point-of-care testing solutions. Regulatory and clinical aspects involve obtaining approvals from regulatory bodies like the NMPA and conducting clinical trials to validate the performance of diagnostic tests. Partnerships with global diagnostic companies are also pursued to expand market reach.

This segment concentrates on developing and commercializing diagnostic solutions for cancer screening, detection, and monitoring. Research and development efforts are focused on creating assays for cancer-related biomarkers and developing early detection methods. Technologies used include real-time PCR, chemiluminescence immunoassay, and advanced molecular diagnostic techniques. The segment aims to improve patient outcomes by enabling early cancer detection and personalized treatment strategies. Sansure Biotech is strategically positioning itself in the cancer diagnostics market through collaborations with genomics companies. Future growth opportunities include expanding the product portfolio to cover a wider range of cancer types and developing companion diagnostics. Regulatory compliance and clinical validation are critical aspects, requiring adherence to stringent quality standards and conducting clinical trials to demonstrate the accuracy and reliability of cancer diagnostic tests. Strategic partnerships with oncology centers and research institutions are also pursued to accelerate product development and market penetration.

This segment is dedicated to developing and providing diagnostic solutions for genetic diseases, including prenatal and postnatal care applications. Research and development activities involve creating tests for genetic mutations and chromosomal abnormalities. Technologies used include PCR-based assays and advanced genetic testing methods. The segment aims to improve patient outcomes by enabling early detection and management of genetic disorders. Sansure Biotech is expanding its presence in the genetic diagnostics market through strategic collaborations. Future opportunities include expanding the product portfolio to cover a wider range of genetic diseases and developing next-generation sequencing (NGS) based tests. Regulatory compliance and clinical validation are critical aspects, requiring adherence to stringent quality standards and conducting clinical trials to demonstrate the accuracy and reliability of genetic tests. Partnerships with genetic counseling centers and hospitals are also pursued to enhance patient care and market reach.